Sickle cell anemia patients display an intricate cellular and serum biomarker network highlighted by tcd4+cd69+lymphocytes, il-17/mip-1 beta, il-12/vegf, and il-10/ip-10 axis by Garcia, Nadja Pinto et al.
UNIVERSIDADE ESTADUAL DE CAMPINAS
SISTEMA DE BIBLIOTECAS DA UNICAMP
REPOSITÓRIO DA PRODUÇÃO CIENTIFICA E INTELECTUAL DA UNICAMP
Versão do arquivo anexado / Version of attached file:
Versão do Editor / Published Version
Mais informações no site da editora / Further information on publisher's website:
https://www.hindawi.com/journals/jir/2020/4585704
DOI: 10.1155/2020/4585704
Direitos autorais / Publisher's copyright statement:
©2020 by Hindawi. All rights reserved.
DIRETORIA DE TRATAMENTO DA INFORMAÇÃO
Cidade Universitária Zeferino Vaz Barão Geraldo




Sickle Cell Anemia Patients Display an Intricate Cellular and
Serum Biomarker Network Highlighted by TCD4+CD69+
Lymphocytes, IL-17/MIP-1β, IL-12/VEGF, and IL-10/IP-10 Axis
Nadja Pinto Garcia ,1,2 Alexander Leonardo S. Júnior ,3 Geyse Adriana S. Soares,4
Thainá Cristina C. Costa,3 Alicia Patrine C. dos Santos,4 Allyson Guimarães Costa ,1,2,3
Andréa Monteiro Tarragô ,2 Rejane Nina Martins,2 Flávia do Carmo Leão Pontes,2
Emerson Garcia de Almeida,3 Erich Vinícius de Paula,3,5 Olindo Assis Martins-Filho,6
and Adriana Malheiro 1,2,3
1Programa de Pós-Graduação em Imunologia Básica e Aplicada, Universidade Federal do Amazonas (UFAM), 69077-000 Manaus,
AM, Brazil
2Laboratório de Genômica, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), 69050-001 Manaus,
AM, Brazil
3Programa de Pós-Graduação em Ciências Aplicadas a Hematologia, Universidade Estadual do Amazonas (PPCAH/UEA), 69065-
001 Manaus, AM, Brazil
4Programa de Apoio a Iniciação Científica, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), 69050-
001 Manaus, AM, Brazil
5Departamento de Clínica Médica da Faculdade de Ciências Médicas da UNICAMP, 13083-970 Campinas, SP, Brazil
6Grupo Integrado de Pesquisas em Biomarcadores, Instituto René Rachou/Fiocruz Minas, 30190-002 Belo Horizonte, MG, Brazil
Correspondence should be addressed to Nadja Pinto Garcia; garcia.nadja@gmail.com
and Adriana Malheiro; malheiroadriana@yahoo.com.br
Received 15 April 2019; Revised 14 November 2019; Accepted 27 November 2019; Published 8 January 2020
Academic Editor: Martin Holland
Copyright © 2020 Nadja Pinto Garcia et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. Sickle cell anemia (SCA) is associated with a chronic proinflammatory state characterized by elevated leukocyte count,
mortality from severe recurrent infections, and subsequent vasoocclusive complications with leukocyte adhesion to the
endothelium and increased plasma levels of inflammatory cytokines. The immune system has a close connection with morbidity
in SCA, but further studies are needed to uncover the involvement of innate and adaptive immunities in modulating the SCA
physiopathology. We performed measurements of the frequency of innate and adaptive immunity cells, cytokines, chemokines,
and growth factors and immunophenotyping of Toll-like receptor and adhesion molecule expression in the blood of SCA
patients and healthy donors to evaluate the different profiles of these biomarkers, the relationship among them, and their
correlation to laboratory records and death risk. Material and Methods. Immunophenotyping of cells, Toll-like receptors, and
adhesion molecules were performed from peripheral blood samples of SCA patients and healthy donors by flow cytometry and
cytokine/chemokine/growth factor measurement by the Luminex technique performed from the serum of the same subjects.
Results. Cells of adaptive immunity such as IL-12, IL-17, and IL-10 cytokines; IL-8, IP-10, MIP-1α, MIP-1β, and RANTES
chemokines; and VEGF, FGF-basic, and GM-CSF growth factors were higher in SCA patients than healthy donors regardless of
any laboratorial and clinical condition. However, high death risk appears to have relevant biomarkers. Conclusion. In the SCA
pathophysiology at steady state, there is a broad immunological biomarker crosstalk highlighted by TCD4+CD69+ lymphocytes,
IL-12 and IL-17 inflammatory and IL-10 regulatory cytokines, MIP-1α, MIP-1β, and IP-10 chemokines, and VEGF growth
factor. High expression of TLR2 in monocytes and VLA-4 in TCD8+ lymphocytes and high levels of MIP-1β and RANTES
appear to be relevant in high death risk conditions. The high reticulocytosis and high death risk conditions present common
correlations, and there seems to be a balance by the Th2 profile.
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1. Introduction
Sickle cell anemia is the most common hemoglobinopathy
(>70% of sickle cell disease in the world) and the most
severe form resulting from homozygous inheritance; a point
mutation of adenine is replaced by thymine (GAG → GTG)
in the sixth codon of the β-globin gene (βS), with valine
replacing glutamic acid at the sixth position of the polypep-
tide chain reflecting as an abnormal form of hemoglobin
(HbS) [1–3].
It is estimated that each year, 300,000 children are born
with a severe form (homozygotes) worldwide, mainly in
sub-Saharan Africa, the Middle East, and India. Migration
patterns led to the distribution of the sickle cell gene to
nonendemic areas of malaria, such as areas in Europe and
the USA. In Brazil in 2016, 1,071 newborn babies had sickle
cell disease (SCD) and >60,000 were heterozygous for the
βS allele. There are an estimated 30,000 individuals with
SCD in the whole country [4–6], and the prevalence of het-
erozygotes for HbS in the North and Northeast regions is
higher at about 6 to 10%, while in the South and Southeast,
the prevalence is lower at 2 to 3% [7, 8].
Sickle cell anemia is associated with a chronic proinflam-
matory state characterized by an elevated leukocyte count,
mortality from severe recurrent infections, and subsequent
vasoocclusive complications such as leukocyte adhesion to
the endothelium and increased plasma levels of inflamma-
tory cytokines [9, 10]. Although patients have the same
genetic mutation for HbS, SCA is characterized by a very het-
erogeneous clinical course, ranging from patients who have
normal life expectancy with relatively few complications such
as pulmonary hypertension, priapism, stroke, leg ulceration,
recurrent painful episodes, acute chest syndrome (ACS),
and avascular necrosis of bone [11–13]. This variability can
partly be explained by genetic modifiers, including factors
that affect HbF level and coinheritance of α-thalassaemia or
by environmental factors [9, 13–15]. The immune system
has a close connection with morbidity in sickle cell anemia,
but further studies are needed to uncover the involvement
of innate and adaptive immunities in modulating the SCA
physiopathology [9, 14].
The main events of the SCA physiopathology are hemo-
lysis and vasoocclusive painful crises due to the complex phe-
nomenon of HbS polymerization essential for the occurrence
of SCA. This phenomenon alters the typical lipid bilayer and
proteins of the erythrocyte membrane, which leads to a
reduction of cellular hydration and changes in the shape
and physical properties of erythrocytes. All these changes will
result in hemolytic anemia, abnormal interactions with other
blood cells, early erythrocyte apoptosis, and blockage of
blood flow, particularly in small (and some large) vessels,
which lead to repeated hypoxia-reperfusion (oxygenation-
deoxygenation) processes further damaging any other organ
[16, 17]. The highly unstable sickle erythrocytes reduce life-
span to ≥75% which induces an increased response of bone
marrow and therefore increased erythropoiesis, reflected by
the high circulation of reticulocytes, which account for
~20% of the red blood cells in individuals with SCA [15,
18]. Hemolysis is thought to occur principally via extravascu-
lar phagocytosis by macrophages, but a substantial fraction
occurs via intravascular hemolysis [15, 19]. The release of
erythrocyte content into plasma by intravascular hemolysis
interferes incisively on vasculopathy with the involvement
of coagulation and immune system components [15].
Vasoconstriction and vascular remodeling in SCA
patients, especially in the lung, are mainly caused by nitric
oxide (NO) depletion. The decrease of NO bioavailability
is caused by Hb (hemoglobin) that scavenges NO, enzyme
NO synthase (NOS) inhibition by asymmetric dimethylar-
ginine (ADMA), and by L-arginine depletion, the substrate
of NOS, by arginase 1 enzyme. The NO deficiency pro-
motes platelet activation and activation of blood clotting
proteins [15, 20].
Heme and other danger-associated molecular pattern
(DAMP) molecules released from erythrocytes activated the
innate immune system. Ligand-bound Toll-like receptor 4
(TLR-4) and TLR-2 activate monocytes and macrophages
to release inflammatory cytokines, which promote an inflam-
matory state and activation of endothelial cells. TLR-4 activa-
tion on platelets promotes their adhesion to neutrophils,
which in turn release DNA to form neutrophil extracellular
traps (NETs). Circulating blood cells adhere to each other
and to the activated endothelium, contributing and poten-
tially even initiating vasoocclusion [21–23].
Limited studies conducted thus far have indicated adap-
tive abnormalities in individuals with SCA. Some abnormal-
ities like reduction in the proportion of circulating CD4+ and
CD8+ T-cells and dysfunction of regulatory T-cells occur
concurrent with increased immune activation and may affect
vaccine reactivity in individuals with SCA [24–27]. It is pos-
sible that geographical differences in the immune system
function may also occur between SCA populations [27].
Considering the divergent information about the com-
plex immune response on the progression of SCA, in this
study we proposed to explore the role of immunological bio-
markers during SCA steady state. So, we performed measure-
ments of the frequency of innate and adaptive immunity
cells, cytokines, chemokines, and growth factors and immu-
nophenotyping of Toll-like receptors and adhesion molecule
expression in the blood of SCA patients and healthy donors
to evaluate the different profiles of these biomarkers, the rela-
tionship among them, and their correlation to laboratory
records and death risk.
2. Subjects, Material, and Methods
2.1. Ethics Statement. All protocols and consent forms were
approved by the Ethical Committees on Research from the
Fundação Hospitalar de Hematologia e Hemoterapia do
Amazonas (HEMOAM) through the protocol CAEE (no.
56413316.9.0000.0009). The subjects involved in the study
signed an informed written consent form in accordance to
Resolution 196/96 of the National Health Board for research
involving human subjects prior to participating.
2.2. Study Population. This study included 100 subjects cate-
gorized into the following two subgroups: the sickle cell ane-
mia (SCA) patient group with 30 subjects at steady state,
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consisting of patients who were not in crises and had not
received blood transfusions in the preceding 3 months and
the healthy donor (HD) group with 70 subjects without any
apparent disease. A nonprobabilistic convenience sampling
was performed to select patients and healthy donors that go
to the Fundação Hospitalar de Hematologia e Hemoterapia
do Amazonas (HEMOAM, Manaus, Amazonas, Brazil) for
treatment and blood donation, respectively, with negative
results for serologic screening tests, including viral hepatitis
(A, B, and C), HIV, syphilis, Chagas disease, and HTLV-
1/2. The SCA patients’ group was composed of subjects of
both genders’ (20 females and 10 males), with ages ranging
from 18 to 49 years (30 ± 8:9), and homozygous to HbS
(HbSS). The HD group was composed of subjects of both
genders’ (52 males and 18 females), with ages ranging from
20 to 61 years (32 ± 10:6). Pregnant women, indigenous peo-
ple, subjects with other hematological diseases (leukemia and
other anemias), subjects undergoing or have been treated for
cancer, and subjects with inflammatory and infectious dis-
eases such as malaria, dengue, Chagas Disease, mycoses,
Zika, Chikungunya, pneumonia, pharyngitis, tonsillitis, and
bronchitis, were not included.
The choice of SCA subgroups was based on the clinical
importance of hemolysis (reticulocytes), hemostasis, and
inflammation (platelets) and clinical complications inherent
to the physiopathology of sickle cell anemia. The associa-
tion of reticulocytosis and thrombocytosis (platelet count
above 400 × 106/mm3) in the clinical severity of this disease
was shown in previous studies [28]. The categorizations of
these subgroups were done by GraphPad Prism version
5.0 software (San Diego, CA, USA) using descriptive analysis
establishing the minimum 25% percentile, the median, and
the maximum 75% percentile. Considering that all patients
present reticulocytosis and thrombocytosis, we classify them
as low (below the median) and high (above the median). The
median of reticulocytes was 400 × 106/mm3 and that of plate-
lets was 450 × 106/mm3. The death risk as calculated by the
“Sickle Cell Disease Severity Calculator,” available from
http://www.bu.edu/sicklecell/downloads/Projects, is described
previously for the calculation of severity scores and the clas-
sification of patients into categories by phenotype (mild,
intermediate, and severe) [13]. However, we did not use
the rating used by Junior et al. in 2015 because the patient
population would be classified as 4/30 as intermediate and
26/30 as severe, which would make it impossible to segregate
patients by robust statistical analysis. Therefore, the criterion
of the median severity score (0.670, 67%) was chosen to clas-
sify the patients as more and less severe, with 15/30 with low
severity (<0.670) and 15/30 with high severity (>0.670).
The clinical and demographical data were acquired by a
standardized questionnaire, and the hematological profile
was assessed by automated blood count carried out at Funda-
ção Hospitalar de Hematologia e Hemoterapia do Amazonas.
The demographic data and hematological and clinical char-
acteristics of patients and healthy donors are summarized
in Table 1.
2.3. Immunophenotypic Analysis of Innate and Adaptive
Components. The immunophenotypic characterization was
performed by a flow cytometry technique. The cells were
obtained from an aliquot of 100μL from peripheral blood
collected with EDTA and were incubated in the presence of
the following fluorescent-labeled specific anti-human cell
surface monoclonal antibodies: anti-CD3FITC/CD8PE/
CD4PercP/CD69APC to identify CD4+ and CD8+ T-cells;
anti-CD4FITC/CD25PercP/FoxP3 AF647 to identify regu-
latory T-cells; anti-CD5FITC/CD19PE to identify B and
B1 cells; anti-CD16FITC/CD56PE/CD3PercP/CD69APC to
identify NK and NKT cells; anti-CD123FITC/CD11cPE to
identify classical and plasmacytoid dendritic cells; anti-
CD14FITC/CD80PE/CD16PercP/HLA-DRAPC to identify
monocyte subtypes; anti-CD14FITC/CD16PercP/CD282PE
TLR2 to identify TLR2 expression in monocytes and neu-
trophils; anti-CD14FITC/CD16PercP/CD284PE to identify
TLR4 expression in monocytes and neutrophils; anti-
CD14FITC/CD16PercP/CD289PE to identify TLR9 expres-
sion in monocytes and neutrophils; anti-CD4FITC/CD11b-
PE/CD3PercP to identify Mac-1 expression in CD4+ T-
cells; anti-CD8FITC/CD11bPE/CD3PercP to identify Mac-
1 expression in CD8+ T-cells; anti-CD4FITC/CD49d-
PE/CD3PercP to identify VLA-4 expression in CD4+ T-
cells; and anti-CD8FITC/CD49dPE/CD3PercP to identify
VLA-4 expression in CD8+ T-cells (antibodies were pur-
chased from BD Biosciences (San Diego, CA, USA), Beck-
man Coulter (Brea, California, USA), and BioLegend (San
Diego, CA, USA)). Following incubation, cells were treated
with 2mL of erythrocyte lysing solution for 7.5 min at room
temperature. After two centrifugation steps and one wash
step with PBS, nonintracellularly labeled cells were resus-
pended in 300μL PBS and intracellularly labeled cells were
incubated with PBS-saponin, followed by a centrifugation
step and resuspension in PBS. Stained cells were stored at
4°C up to 24h prior to flow cytometric acquisition. A total
of 30,000/100,000 events were acquired for each blood sam-
ple to quantify cell types.
The sample acquisition was performed on the FACSCa-
libur® Flow Cytometer (Becton, Dickinson and Company,
San Jose, CA, USA) of the Fundação HEMOAM. For the
morphometric and immunophenotypic identification of the
cells, the FlowJo Software (version 7.2) was used, with the
design of the gates to select the target populations in graphs
that combine morphological characteristics (size and granul-
osity) with immunophenotypic characteristics through the
fluorescence of the monoclonal antibodies used to identify
the target cells.
2.4. Cytokines, Chemokines, and Growth Factor Analysis. The
serum cytokines IL-1β, IL-6, TNF-α, IL-12, IFN-γ, IL-2, IL-7,
IL-4, IL-5, IL-13, IL-17, and IL-10; chemokines IL-8, IP-10,
MIP-1α, MIP-1β, MCP-1, and RANTES; and growth factors
VEGF, FGF-basic, PDGF, GM-CSF, and G-CSF were mea-
sured using Bio-Plex Pro Human Cytokine 27-Plex Kit
(Bio-Rad, California, USA) following the manufacturer’s
instructions by Luminex assay. Data acquisition and analysis
were performed using Luminex 200 System equipment and
Bio-Plex Manager Software, respectively. The results were
expressed as pg/mL, as assessed by the standard curve using
the fifth-logistic regression parameter. The limits of detection
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were IL − 1β = 8:608 pg/mL, IL − 6 = 37:680 pg/mL, TNF −
α = 64:803 pg/mL, IL − 12 = 37:684 pg/mL, IFN − γ = 25:411
pg/mL, IL − 2 = 18:297 pg/mL, IL − 7 = 16:593 pg/mL, IL −
4 = 4:789 pg/mL, IL − 5 = 23:105 pg/mL, IL − 13 = 8:090 pg/
mL, IL − 17 = 28:850 pg/mL, IL − 10 = 35:170 pg/mL, IL −
8 = 42:150 pg/mL, IP − 10 = 31:236 pg/mL, MIP − 1α = 960
Table 1: Study population.
Characteristics Healthy donors HD (n = 70) SCA patients (n = 30) p value∗
Demographic and epidemiological data
Gender, male/female (%) 52/18 (74/26) 10/20 (33/67) —
Age (mean ± SD) 32 ± 11 30 ± 9 —
Residence (%)
Autazes (AM) 2 (6) —
Apuí (AM) 1(3) —
Bacabau (MA) 1(3) —
Belém (PA) 3 (10) —
Itacoatiara (AM) 1(3) —
Manacapuru (AM) 3 (10) —
Manaquiri (AM) 1 (3) —
Manaus (AM) 11 (36) —
Monte Alegre (PA) 1 (3) —
Óbidos (PA) 2 (6) —
Oriximiná (PA) 2 (6) —
Tefé (AM) 1 (3) —
Ignored 2 (6) —
Hematological records (median, range)
Hematocrit (%) 44.75 (35.0-45.1) 24.4 (3.7-33.8) p < 0:0001
Hemoglobin levels (g/dL) 15.15 (11.4-15.6) 7.95 (1.3-11.4) p < 0:0001
White blood cells × 106/mm3 6.0 (3.4-6.6) 7.13 (2.5–12.5) p = 0:05
Red blood cells × 106/mm3 5.07 (4.1-5.6) 2.47 (0.7-4.5) p < 0:0001
MCV (fL)∗∗ 87.7 (71.2-92.0) 99.25 (68.6-123.3) p < 0:0001
MCH (pg)∗∗ 29.8 (24.8-29.7) 31.9 (20.1-42.0) p = 0:0002
CHCM (g/dL)∗∗ 34.2 (31.0-34.6) 33.6 (30.4-35.2) p = 0:0008
RDW (%)∗∗ 13.8 (11.9-14.2) 18.2 (15.2-25.6) p < 0:0001
Platelets × 106/mm3 246 (100-300) 421 (146.8-859.0) p < 0:0001
MPV (fL)∗∗ 7.75 (5.8-8.9) 7.6 (6.0-9.5) p = 0:4699
Reticulocytes (%) — 16.32 (4.2-34.8) —
Reticulocytes × 106/mm3 — 387.45 (163.1-792.6) —
Signals and symptoms (%)
Headache — 19 (63) —
Joint pain — 19 (63) —
Weakness — 18 (60) —
Jaundice — 17 (57) —
Leg ulcers — 10 (33) —
Vasoocclusive crises — 11 (37) —
Cholelithiasis — 8 (27) —
Splenic sequestration — 6 (20) —
Acute thoracic syndrome — 8 (27) —
Pulmonar hypertension — 7 (23) —
Femur head osteonecrosis — 5 (17) —
∗Nonparametric test of Mann-Whitney. ∗∗Hematimetric indices: MCV—mean corpuscular volume; MCH—mean corpuscular hemoglobin; CHCM—mean
corpuscular hemoglobin concentration; RDW—red cell distribution width; MPV—mean platelet volume.
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pg/mL, MIP − 1β = 11:233 pg/mL,MCP − 1 = 24:282 pg/mL,
RANTES = 16:533 pg/mL, VEGF = 29:464 pg/mL, FGF −
basic = 16:046 pg/mL, PDGF = 24:721 pg/mL, GM − CSF =
12:844 pg/mL, and G − CSF = 40:049 pg/mL.
2.5. Data Analysis and Conventional Statistics. All data were
considered as presenting a nonparametric distribution, and
therefore, the comparative analyses about the frequency of
cells and levels of cytokines, chemokines, and growth factors
were compared between HD and SCA groups by the Mann-
Whitney two-tailed test. Analyses between the low and high
subgroups were performed using the ANOVA variance anal-
ysis, followed by the Kruskal-Wallis test, and followed by
Dunn’s multiple comparison test. A 95% confidence interval
was used, and the data considered with statistical significance
were those with p value < 0.05. The GraphPad Prism software
version 5.0 (San Diego, CA, USA) was used for data analysis.
2.6. Biomarker Signature Analysis. The cellular and serum
biomarker ascendant signatures were assembled as previ-
ously reported by Luiza-Silva et al. [29]. This model of anal-
ysis allows converting continuous measurements into a
categorical analysis. Initially, the whole universe of data of
each biomarker was used to calculate the global median value
used as the cut-off to classify each subject as the present
values below or above the cut-off edge. Thereafter, the ascen-
dant signatures of the cell phenotype features and serum
immunological biomarkers were assembled considering the
frequency of subjects with values above the global median
cut-off determined for each biomarker. Overlays of ascen-
dant biomarker signature curves were employed to identify
those biomarkers with the frequency of subjects above the
50th percentile, further highlighted for subsequent Venn dia-
gram analysis to identify those biomarkers commonly or
selectively observed among groups. The GraphPad Prism
5.0 software (San Diego, USA) was used for graph arts.
2.7. Biomarker Network Assembly. Biomarker networks were
assembled to evaluate the multiple associations among the
cells and cytokines/chemokines/growth factors in the SCA
patients and subgroups. The association between the quan-
titative levels of cells, cytokines, chemokines, and growth
factors were determined by the Spearman correlation coef-
ficient in GraphPad Prism 5.0 software (San Diego, USA),
and statistical significance was considered only if p < 0:05.
After performing the correlation analysis between bio-
markers, a database was created on the Microsoft Excel pro-
gram 2010. Then, the significant correlations were compiled
using the open access software Cytoscape (version 3.6.1) as
previously reported. The biomarker networks were con-
structed using circular nodes for each cell, cytokine, chemo-
kine, and growth factor, including white circles to HD,
black circles to SCA, light grey circles to low subgroups,
and dark grey circles to high subgroups assembled in circular
layouts. The correlation indices (r) were used to categorize
the correlation strength as negative (r < 0), moderate
(0:36 ≥ r ≤ 0:68), and strong (r > 0:68) represented by con-
necting edges as proposed by Taylor [30].
3. Results
3.1. Major Phenotypic Features of Innate and Adaptive
Immunity in Patients with Sickle Cell Anemia. The innate
immunity cell phenotypes in SCA patients are presented in
Figure 1. The low frequency of neutrophils and classical
and plasmacytoid DCs, along with the decreased percentage
of NK and NKT cells, were observed in SCA as compared
to HD (Figure 1(a)). Conversely, the increased frequency
of activated inflammatory monocytes (CD14+CD16+HLA-
DR+) and B1 lymphocytes as well as the enhanced expression
of TLR-9 by neutrophils and monocytes were also observed
in SCA patients (Figures 1(a) and 1(b)). Phenotypic features
of adaptive immunity cells are presented in Figure 2. Data
analyses demonstrated the high frequency of lymphocytes,
activated TCD4+, TCD8+, TCD4+/TCD8+ ratio, and B lym-
phocytes and the high expression of Mac-1 in TCD4+ cells in
SCA patients compared to HD (Figures 2(a) and 2(b)). Fur-
thermore, decreased levels of CD4+ and CD8+ lymphocytes,
besides the decreased expression of Mac-1 in TCD8+ cells
were also observed in the SCA group (Figures 2(a) and 2(b)).
3.2. Phenotypic Features of Innate and Adaptive Immunity in
Patients with Sickle Cell Anemia according to Laboratorial
and Clinical Records. Aiming at further characterizing the
profile of innate and adaptive immunity cells in SCA, the
patients were categorized according to their laboratorial
and clinical records, including reticulocyte counts, platelet
levels, and death risk scores. The results are presented in
Figure 3. The reference values observed in HD are presented
as the interquartile range (25th-75th) for each cell phenotype
evaluated (Figure 3, gray background). Data analysis demon-
strated that the high frequency of activated inflammatory
monocytes (CD14+CD16+HLA-DR+) and increased expres-
sion of TLR9 by neutrophils and monocytes are observed in
SCA patients regardless of the laboratorial and clinical condi-
tions. Moreover, lower levels of classical and plasmacytoid
DCs, besides NK and NKT cells, were also found in SCA
patients regardless of the presence of reticulocytosis, throm-
bocytosis, and high death risk (Figures 3(a) and 3(b)). The
SCA patients with a high platelet count showed an elevated
frequency of activated neutrophils and increased expression
of TLR2 by monocytes compared to HD (Figures 3(a) and
3(b)). Furthermore, the enhanced expression of TLR2 by
monocytes was observed in SCA patients with a high death
risk score (Figure 3(b)).
The analysis of adaptive immunity cells revealed that
despite the low levels of CD4+ T-cells and CD8+ T-cells,
SCA patients exhibited a high frequency of CD4+CD69+ T-
cells, CD8+CD69+ T-cells, and CD19+ B-cells regardless of
the laboratorial/clinical score (Figure 3(c)). In addition, the
results demonstrated that Mac-1 expression by CD8+ T-
cells was significantly lower in SCA patients with low reticu-
locyte counts (Figure 3(d)). Moreover, increased VLA-4
expression by CD8+ T-cells was found in SCA with a high
death risk score (Figure 3(d)). Remarkably, SCA patients
with high death risk presented an increased expression of
TLR2 by monocyte and VLA-4 by CD8+ T-cells in compar-
ison with those SCA patients presenting low death risk
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(Figures 3(b) and 3(d)). Conversely, SCA patients with low
reticulocyte counts showed decreased expression of Mac-1
by CD8+ T-cells as compared to patients with high reticulo-
cyte counts (Figure 3(d)).
3.3. Serum Immunological Biomarkers in Sickle Cell Anemia
Patients. The profile of serum cytokines, chemokines, and
growth factors observed in SCA patients are shown in

















































































































(a) Innate immune cell phenotype in SCA patients
(b) Toll-like receptor expression in SCA patients
Figure 1: Phenotype profile of innate immunity in SCA patients. The frequency of cell phenotypes (a) and Toll-like receptor expression (b)
were measured in peripheral blood of SCA patients and healthy donors by flow cytometry. The results are shown in scatter plots with
individual values, and the median percentage of cells or mean fluorescence intensity (MFI) is represented as a line. Significant differences
(p < 0:05) are highlighted by connecting lines and asterisks (∗) for comparison with the HD group.
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overall increase of most immunological biomarkers evalu-
ated, include IL-1β, IL-6, IL-12, IFN-γ, IL-4, IL-17, IL-10,
IL-8, IP-10, MIP-1α, MIP-1β, RANTES, VEGF, FGF-basic,
and GM-CSF as compared to HD (Figures 4(a)–4(c)).
Decreased levels of IL-2 and IL-13 were also observed in
SCA patients (Figure 4(a)). Unaltered levels of TNF-α, IL-7,
IL-5, MCP-1, and G-CSF were found in serum samples from
SCA patients as compared to HD (Figures 4(a)–4(c)).
3.4. Serum Immunological Biomarkers in Patients with Sickle
Cell Anemia according to Laboratorial and Clinical Records.
The serum levels of cytokines, chemokines, and growth fac-
tors were further evaluated in SCA patients categorized
according to their laboratorial and clinical records, and data
are shown in Figure 5. The reference values observed in HD
are presented as the interquartile range (25th-75th) for each
immunological biomarker analyzed (Figure 5, gray back-
ground). Increased levels of IL-1β, IFN-γ, IL-12, IL-17, IL-
10, IL-8, IP-10, MIP-1α, and VEGF but low levels of MIP-
1β were observed in SCA patients regardless of the laborator-
ial and clinical scores as compared to HD reference ranges.
The high concentrations of IL-6, RANTES and G-CSF were
shown in SCA patients regardless of the reticulocyte counts.
TNF-α, IL-2, and GM-CSF were increased in SCA patients
with low reticulocyte counts. IL-4, IL-13, and FGF-basic
were detected in SCA patients with high reticulocyte counts
as compared to HD reference ranges. High levels of IL-6
were demonstrated in SCA patients with low platelet
counts. Enhanced levels of IL-2, IL-7, IL-4, and GM-CSF
were observed in SCA patients with high platelet counts
as compared to HD reference ranges. Increased levels of
IL-6, IL-4, IL-13, MCP-1, and GM-CSF were found in
SCA patients with high death risk as compared to HD ref-
erence ranges. Remarkably, SCA patients with high death
risk presented increased levels of IL-10, IP-10, MIP-1α,
MIP-1β, and RANTES in comparison with those of SCA
patients presenting low death risk. Likewise, SCA patients
with high platelet counts presented increased levels of IL-17


























(a) Adaptative immune cell phenotype in SCA patients
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Figure 2: Phenotype profile of adaptive immunity in SCA patients. The frequency of cell phenotypes (a) and adhesion molecule expression
(b) were measured in peripheral blood of SCA patients and healthy donors by flow cytometry. The results are shown in scatter plots with
individual values, and the median percentage of cells or mean fluorescence intensity (MFI) is represented as a line. Significant differences
(p < 0:05) are highlighted by connecting lines and asterisks (∗) for comparison with the HD group.
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(a) Innate immune cell phenotype in SCA subgroups
(c) Adaptative immune cell phenotype in SCA subgroups
(d) Adhesion molecules in SCA subgroups
Figure 3: Phenotype profile of innate and adaptive immunity components in SCA subgroups according to laboratorial and clinical records.
The frequency of cell phenotypes (a), the expression of Toll-like receptors (b) by innate immunity cells along with the cell phenotypes (c), and
the expression of adhesion molecules by adaptive immunity cells (d) were analyzed in SCA subgroups by flow cytometry. The SCA patients
were categorized according to their laboratorial and clinical records, including reticulocyte counts, platelet levels, and death risk scores. The
results are presented in box plots with median and interquartile range overlaid by scatter plots with individual values for cell phenotype or
mean fluorescence intensity (MFI). The interquartile ranges (25th-75th) for results observed in HD were used as reference range (gray
background). Significant differences (p < 0:05) are highlighted by connecting lines and asterisks (∗).
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and MIP-1α as compared to those with low platelet counts
(Figures 5(a)–5(c)).
3.5. Signatures of Cell Phenotype Features and Serum
Immunological Biomarkers in Patients with Sickle Cell
Anemia according to Laboratorial and Clinical Records. The
signatures of cell phenotype features and serum immunolog-
ical biomarkers were assembled as the frequency of subjects
with values of cells from innate and adaptive immunity or
serum biomarkers above the global median cut-off, aiming
at identifying the attributes that characterize the immunolog-
ical profile of SCA patients and their respective laboratorial
and clinical records. According to this categorical descriptive
analysis, it was possible to select the most relevant bio-
markers observed in more than 50% of the subjects on each
group (Figure 6—gray background). Data analysis demon-
strated that in general the SCA patients presented higher
number biomarkers above the 50th percentile as compared
to HD (Figure 6(a)). Slight differences were observed in the
number of cellular biomarkers above the 50th percentile
while comparing the SCA subgroups (Figure 6(b)).
Venn diagram analyses further demonstrated that a set of
cell phenotype features were commonly observed in more
than 50% of the SCA patients, regardless of their laboratorial
(a) Serum cytokines in SCA patients



































































































































(c) Serum growth factors in SCA patients
Figure 4: Serum immunological biomarkers in sickle cell anemia patients. The levels of cytokines (a), chemokines (b), and growth factors (c)
were measured in sera of SCA patients and healthy donors by Luminex assay. The results are shown in bar charts with mean ± standard
deviation for serum concentration (pg/mL). Significant differences (p < 0:05) are highlighted by connecting lines and asterisks (∗).
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and clinical records, including CD14+CD16+MON, CD4
+CD69+, and CD8+CD69+ (Figure 6(b)—black squares).
Furthermore, specific biomarkers were selectively identified
in the ascendant signatures of SCA patients with low reticu-
locyte counts, high platelet counts, and high death risk,
including CD8+CD11b+, CD11b+NEU, CD8+CD49d+,
and TLR2MON, respectively (Figure 6(b)).
A clear cytokine storm was observed in SCA patients
as compared to HD. Data analysis demonstrated that
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(a) Serum cytokines in SCA subgroups
(b) Serum chemokines in SCA subgroups
(c) Serum growth factors in SCA subgroups
Figure 5: Serum immunological biomarkers in sickle cell anemia patients according to laboratorial and clinical records. The levels of
cytokines (a), chemokines (b), and growth factors (c) were measured in sera of SCA subgroups by Luminex assay. The SCA patients were
categorized according to their laboratorial and clinical records, including reticulocyte counts, platelet levels, and death risk scores. The
results are presented in box plots with median and interquartile range overlaid by scatter plots with individual serum concentration
(pg/mL). The interquartile ranges (25th-75th) for results observed in HD were used as reference range (gray background). Significant
differences (p < 0:05) are highlighted by connecting lines and asterisks (∗).
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immunological biomarkers as observed by the frequency of
subjects with levels above the 50th percentile as compared
to HD (Figure 6(c)). Comparative analysis between SCA sub-
groups demonstrated that SCA patients with a high death
risk display a higher number of altered biomarkers as com-
pared to those with a low death risk (Figure 6(d)). Venn dia-
gram analyses demonstrated that a set of serum biomarkers
were commonly observed in more than 50% of the SCA
patients, regardless of their laboratorial and clinical records,
including IL-8, IP-10, IL-12, and IL-10 (Figure 6(d)—black
squares). However, no selective biomarkers could be identi-
fied for a given SCA subgroup (Figure 6(d)).
3.6. Cell Phenotypes and Serum Biomarker Networks in
Patients with Sickle Cell Anemia according to Laboratorial
and Clinical Records. Aiming at characterizing the integrative
and multiparametric analysis of the immune response in
SCA patients, a correlation analysis between cell pheno-
types as well as among serum biomarkers was carried out
and the network profiles assembled according to the nega-
tive or positive correlations between pairs of attributes
(Figures 7, 8, and 9). Data demonstrated that SCA patients
presented a complex and intricate cell phenotype network
rich in negative connections compared to HD (Figure 7(a)).
In fact, while HD displayed a strong correlation between
innate immunity receptors and Treg cells, the SCA patients
displayed positive connections between CD4+CD69+T and
CD8+CD69+, TLR4NEU, TLR4MON, and TLR9MON
along with others involving TLR4NEU, TLR2NEU,
TLR4MON, and TLR2MON.
Analysis of serum biomarker networks revealed that a
small number of positive edges were observed in SCA
patients as compared to HD (Figure 7(b)). It was noticed that















































































































































































































































































































































































































































































(d) Serum biomarker signature in SCA subgroups
(b) Cellular biomarker signature in SCA subgroups(a) Cellular biomarker signature in
SCA patients









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 6: Signatures of cell phenotype features and serum immunological biomarkers in patients with sickle cell anemia according to
laboratorial and clinical records. The signatures of cell phenotype features (a, b) and serum immunological biomarkers (c, d) were
assembled considering the frequency of subjects with values above the global median cut-off determined for each biomarker. The SCA
patients were categorized according to their laboratorial and clinical records, including reticulocyte counts, platelet levels, and death risk
scores. The global median values for each biomarker were used as the cut-off to classify each subject with “low” or “high” biomarker levels.
Overlay of ascendant biomarker signature curves was employed to identify those biomarkers with frequency of subjects above the 50th
percentile (dashed lines) further highlighted by gray background. Venn diagram analyses were carried out to identify those biomarkers
commonly or selectively observed among groups. The universal biomarkers observed in all SCA subgroups were tagged by black squares.
Those biomarkers with putative association with SCA subgroups were tagged with a gray diamond for SCA patients with low reticulocyte
counts, a dark gray circle for SCA patients with high platelet counts, or a dark gray triangle for SCA patients with high death risk.






















































(a) Cellular biomarker networks in sickle cell anemia


















































Negative weak (r > –0.36)
Negative moderate (–0.68 ≥ r ≤ –0.36)
Negative strong (r ≤ –0.68)
Positive weak (r < 0.36)
Positive moderate (0.36 ≥ r ≤ 0.68)
Positive strong (r ≥ 0.68)
Figure 7: Cellular and serum biomarker networks in SCA patients. Customized biomarker network layouts for SCA patients (black nodes)
and HD (white nodes) were assembled to identify the relevant association between innate and adaptive cell phenotypes (a) and serum
biomarkers (b) using circular distribution of nodes. Significant Spearman’s correlations at p < 0:05 were represented by connecting edges
to highlight positive (strong (r ≥ 0:68; thick continuous line), moderate (0:36 ≥ r ≤ 0:68; not so thick continuous line), or weak (r < 0:36;
thin continuous line)) and negative (strong (r≤−0:68; thick dashed line), moderate (−0:68 ≥ r≤−0:36; not so thick dashed line), or weak
(r>−0:36; thin dashed line)) as proposed by Taylor [30].


















































































































































































































































































































Cellular biomarker networks in sickle cell anemia subgroups
Correlation indices
Ret low Ret high
PLT low PLT high
Death risk low Death risk high
Negative weak (r > –0.36)
Negative moderate (–0.68 ≥ r ≤ –0.36)
Negative strong (r ≤ –0.68)
Positive weak (r < 0.36)
Positive moderate (0.36 ≥ r ≤ 0.68)
Positive strong (r ≥ 0.68)
Figure 8: Cell phenotype networks in patients with sickle cell anemia according to laboratorial and clinical records. The SCA patients were
categorized according to their laboratorial and clinical records, including reticulocyte counts (RET), platelet levels (PLT), and death risk
scores. Customized biomarker network layouts were assembled to identify the relevant association between innate and adaptive cell
phenotypes for SCA patients with low (light gray nodes) or high (dark gray nodes) levels. Clinical and laboratorial records were assembled
to identify the relevant association between innate and adaptive cells using the circular distribution of nodes. Significant Spearman’s
correlations at p < 0:05 were represented by connecting edges to highlight positive (strong (r ≥ 0:68; thick continuous line), moderate
(0:36 ≥ r ≤ 0:68; not so thick continuous line), or weak (r < 0:36; thin continuous line)) and negative (strong (r≤−0:68; thick dashed line),
moderate (−0:68 ≥ r≤−0:36; not so thick dashed line), or weak (r>−0:36; thin dashed line)) as proposed by Taylor [30].





































































































































Serum biomarker networks in sickle cell anemia subgroups
Ret low Ret high
PLT low PLT high
Death risk low Death risk high
Correlation indices
Negative weak (r > –0.36)
Negative moderate (–0.68 ≥ r ≤ –0.36)
Negative strong (r ≤ –0.68)
Positive weak (r < 0.36)
Positive moderate (0.36 ≥ r ≤ 0.68)
Positive strong (r ≥ 0.68)
Figure 9: Serum biomarker networks in patients with sickle cell anemia according to laboratorial and clinical records. The SCA patients were
categorized according to their laboratorial and clinical records, including reticulocyte counts (RET), platelet levels (PLT), and death risk
scores. Customized biomarker network layouts were assembled to identify the relevant association between innate and adaptive cell
phenotypes for SCA patients with low (light gray nodes) or high (dark gray nodes) levels. Clinical and laboratorial records were assembled to
identify the relevant association between serum cytokines, chemokines, and growth factors using circular distribution of nodes. Significant
Spearman’s correlations at p < 0:05 were represented by connecting edges to highlight positive (strong (r ≥ 0:68; thick continuous line),
moderate (0:36 ≥ r ≤ 0:68; not so thick continuous line), or weak (r < 0:36; thin continuous line)) and negative (strong (r≤−0:68; thick
dashed line), moderate (−0:68 ≥ r≤−0:36; not so thick dashed line), or weak (r>−0:36; thin dashed line)) as proposed by Taylor [30].
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immune response and made an interesting triad between
IL-10, IL-12, and VEGF, whereas in SCA patients, IL-10
displayed a relevant loss of connections with only a strong
positive connection with IP-10 remaining, which was not
observed in HD. In SCA, interesting triads are observed,
including IFN-γ/IL-12/VEGF, IL-12/IL-17/MIP-1β, and
IL-1β/IFN-γ/TNF-α, suggesting an intense inflammatory
response.
The cellular networks assembled for SCA subgroups
according to laboratory and clinical records are presented
in Figure 8. The results demonstrated that SCA patients with
high reticulocyte counts (RET high subgroup) presented a
stronger network compared to those with low reticulocyte
counts (RET low subgroup). On the other hand, SCA
patients with high platelet counts or high death risk pre-
sented a significant loss of connection. Interestingly, patients
with high reticulocyte counts and high death risk presented
strong connections such as TLR9NEU/B-cell/TLR9MON
and CD4+CD69+T/TLR4MON. The SCA subgroup with
low platelet counts has a peculiar network with a relevant
increase of negative connections (Figure 8).
The serum biomarker network assembled for SCA
subgroups according to laboratory and clinical records are
presented in Figure 9. Data analysis demonstrated that in
general, SCA patients presented positive connections
between the pairs IL-17/MIP-1β, IL-12/VEGF, and IL-
10/IP10, regardless of their laboratorial records. It was
noticed that although IL-10 makes few connections, the
IL-10/IP-10 link is observed in all SCA subgroups. SCA
subgroups with high reticulocyte counts presented stronger
connections as compared to those with low reticulocyte
counts. However, SCA subgroups presented strong bio-
marker connections regardless of their platelet counts or
death risk scores (Figure 9). SCA patients with high reticulo-
cyte counts and high death risk presented a more similar net-
work highlighted by common connections such as the TNF-
α/IL-1β/MIP-1α triad, the IFN-γ/IL-13, IL-17/IL-4 triad, and
the IL-4/IL-2 axes. The SCA patients with high platelet
counts displayed a more peculiar network mediated by sev-
eral positive connections (Figure 9).
4. Discussion
The sickle cell anemia is a complex clinical syndrome
caused by the presence of HbS and erythrocyte injury that
leads to extra- and intravascular hemolysis, inflammation,
endothelial dysfunction, and vasculopathy, accompanied
by heterocellular leukocyte-platelet-erythrocyte-endothelial
adhesive events that trigger vasoocclusive episodes of small
and large blood vessels producing acute organ ischemia and
reperfusion injury [22]. Many studies have confirmed the
association of indirect markers of hemolysis with certain
complications of disease. Belini Junior et al. [13] in their
study about the severity of Brazilian sickle cell disease
patients showed that in all patients the relationship of reticu-
locytes, hemoglobin, leucocytes, LDH, bilirubin, and HbS
biomarkers with severity score was statistically significant;
that is, SDC severity is associated with these markers. Our
SCA patients at steady state presented an intense reticulocy-
tosis, and when we evaluate the immunologic biomarkers in
this condition, the relation between these markers is very
similar in the high death risk condition.
The immune abnormalities in SCA can contribute to
vasoocclusive crises and increase susceptibility to infection
and may potentially explain incidences of impaired magni-
tude or duration of responses to vaccines. These conditions
lead to significant morbidity and/or risk of death in individ-
uals with SCA [9, 13, 27, 31]. In this study, we analyzed cells,
receptors, adhesion molecules, cytokines, chemokines, and
growth factors of innate and adaptive immunities from
SCA patients aiming to better understand the involvement
of the immune response in the pathophysiology and morbid-
ity of SCA and thus identify immunological biomarkers that
may be related to laboratory conditions and clinical severity
of SCA.
Our results explicitly show that patients with SCA at
steady state have a high frequency of adaptive immune cells
rather than innate immune cells. Although TCD4+ and
TCD8+ lymphocytes were significantly decreased in SCA
patients compared to the HD group, the frequency of these
activated cells was significantly higher in patients compared
to the HD group regardless the low and high laboratory
and clinical conditions evaluated. The value of T-cell subsets
in patients with homozygous SCA is variable [32]. Koffi et al.
in 2003 showed that CD8+ T-cells significantly increased and
there was no difference between CD4+ T-cells in SCA
patients compared to their control group [32]. However,
Kaaba and Al-Harbi in 1993 and Vingert et al. in 2015 also
showed a lower frequency of TCD4+ and CD8+ T-cells in
SCA patients compared to HD individuals [25, 33]. The
reduction in the proportion of circulating CD4+ and CD8+
cells was shown to be more profound in the presence of
splenic defects, and SCA is invariably accompanied by
hyposplenism [27, 32].
The TCD4+/TCD8+ ratio was higher in SCA patients
than the HD group, indicating that there is an increased
absolute number of TCD4 cells and fewer TCD8 cells in
SCA patients (this means a normal ratio). However, a rever-
sal of the normal ratio, that is a relative increase in the
number of TCD8+ lymphocytes in SCA patients has been
shown by Adedeji in 1985 [34]. Even though these cells
were more activated in SCA patients indicating that they
are acting on the immune response [25]. Rêgo et al. [35]
and Vingert et al. [24] reported in their works of an increase
in the regulatory T-cell (CD4+CD25+FoxP3+) frequency in
SCD patients compared to the HD group. However, this
increase can be related to previous blood transfusion or to
the body’s attempt to minimize inflammation intrinsic to
SCA [24, 35, 36]. Our results show that Tregs appear to
be increased in SCA patients compared to HD, but this dif-
ference was not significant.
The Mac-1 molecule is very important for mediating the
interaction between RBC and adherent leucocytes and pro-
motes vasoocclusion in SDC. It was observed by Chen et al.
that Mac-1 deficiency significantly prolonged the survival of
SCD mice during and after the experimental procedure
[37]. Our results showed that TCD4+CD11b+ may have an
effective participation in the process of endothelium
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adhesion and occlusive vessel crisis regardless of reticulocy-
tosis, thrombocytosis, and death risk in contrast to the
TCD8+ lymphocyte that had a low expression of Mac-1 com-
pared to the HD group.
The VLA-4 molecule (CD49d) is the only integrin
maintained on the surface of young SS erythrocytes and
reticulocytes, which are increased in the peripheral blood
of SDC patients and mediate the adhesion of these cells to
the endothelium [38]. Canalli et al. [39] demonstrated that
VLA-4 in neutrophils, despite its low expression, participates
in the in vitro adhesion of sickle cell disease neutrophils to
endothelial layers under both basal and tumor necrosis fac-
tor-α-stimulated conditions. Our results showed no differ-
ence in VLA-4 expression either of the TCD4+ or TCD8+
lymphocytes in SCA patients compared to the HD group,
but it appears to be increased in CD4+ T lymphocytes. How-
ever, when we evaluated this marker in the laboratory and
clinical conditions of SCA, the high VLA-4 expression in
TCD8+ appears to be a selective biomarker for high death
condition, as also shown by signature analyses. The higher
expression of VLA-4 in TCD8+ lymphocytes increases its
adhesion to vascular endothelium, affecting the microenvi-
ronment through cytokines and interactions with other cell
types and extracellular matrix [40].
Several studies have shown that the proportions of circu-
lating B-cells in SCA are generally unaltered [27, 41, 42].
Venkataraman and Westerman [43] showed no significant
changes in the percentage of B-cells in SCA patients at steady
state compared to control group individuals; however, they
showed that changes in in vitro B cell function occur during
vasoocclusive pain crises in SCA patients. Unlike the cited
data, we observed in our work a significant increase in the
frequency of B (CD5-CD19+) in SCA patients at steady state
regardless reticulocytosis, thrombocytosis, and death risk
conditions compared to HD. Kaaba and Al-Harbi [33] and
Bao et al. [44] have also observed increases in B-cells in
SCA patients at steady state, and they claim that higher num-
bers of B lymphocytes are observed in adults with SCA with
increased circulatory Th2 cytokines, IL-4 and IL-10. The
multiple blood transfusions in SCA patients can induce B-
cell differentiation and immunoglobulin secretion and conse-
quently alloimmunization [27].
About innate immunity cells, our results showed a lower
frequency of total neutrophil count and no difference in the
frequency of total monocyte count compared to healthy
donors unlike those of several studies [45–49]. However, in
the SCA patients evaluated in our work, the neutrophils
appear to be more activated (CD11b+) than HD. Increasing
evidence indicates that (activated) neutrophils could play
an important role in the initiation and propagation of
vasoocclusive processes in SCD [50]. Lard et al. [50] and
Kerst et al. [51] observed a similar result with a decrease in
neutrophil count that was most likely caused by activated
neutrophils due to the high expression of the CD11b mole-
cule and consequently greater adhesion to the vascular endo-
thelium. So, neutrophils may have left the circulation and are
therefore underrepresented in the blood. Through our analy-
ses, we observed activated neutrophils expressing CD11b+ at
a high frequency in high thrombocytosis and making rare
connections with other markers. So, it appears that neutro-
phils expressing CD11b+ in our SCA patients at steady state
are aggregated with platelets. Platelets can also bind to eryth-
rocytes, monocytes, and neutrophils to form aggregates.
Between monocyte subsets, only activated inflamma-
tory monocytes (CD14+CD16+HLA-DR+) were signifi-
cantly elevated in SCA patients. Singhal et al. [52] showed
similar results to our work, which observed a very low count
of total monocytes and a high percentage for inflammatory
monocytes (CD14+CD16+HLA-DR+). In SDC patients,
monocytes presented a significant expression of phosphati-
dylserine on the surface indicating the probability of the
early activation of apoptosis, which could be a possible rea-
son for the low counts of these cells in patients [52].
Annarapu et al. also described in their study that when
CD14+monocytes are engulfed by the Hb-activated platelets,
a frequent and characteristic condition of SCA [53], they
were transformed into the highly inflamed CD14+CD16+
subtype. This condition may be happening in our SCA
patients at steady state.
We observed a high frequency of B1 cells (CD5+CD19+)
in SCA patients compared to HD. Human B1 cells (CD5
+CD19+) spontaneously secrete IgM and express an Ig reper-
toire targeted to a narrow range of antigens such as phos-
phorylcholine and DNA [54]. These cells also promote
homeostasis and can modulate the immune response by
secreting the anti-inflammatory cytokine IL-10. Natural
IgM produced by B1 cells has been shown to promote inflam-
mation by activating the classical complement cascade and
cause tissue destruction by binding to epithelial antigens
exposed upon ischemia-reperfusion injury [55]. Possibly by
this mechanism, B1 lymphocytes are contributing to the
pathophysiology of SCA. Furthermore, it was shown by
Paglieroni et al. [56] that in SCA patients who had received
blood transfusion but who have not received a transfusion
within 3 months, there were significant differences in CD5+
B-cell (B1 cell) percentages and absolute numbers compared
to healthy never-transfused blood donors.
Among Toll-like receptors, only TLR9 in both neutro-
phils and monocytes was highly expressed. Pitanga et al.
[57] showed a higher expression of TLR2 and TLR4 genes
and no differences in TLR9 expression in PBMC of 12 SCA
patients at steady state. Although they did not analyze TLR
proteins, they believe that the continuous exposure to SS-
RBC can affect TLR pathways. Some authors have described
that certain conditions, such as elevated IL-4 and IL-10 or an
inappropriate concentration of a given stimulus (TLR2 and
TLR4 agonists), are not sufficient to induce TLR2 and
TLR4 upregulation on the surface of monocytes and neutro-
phils possibly because the baseline expression of these recep-
tors might be sufficient and an upregulation would only
occur after higher stimulus [58–60]. However, we observed
through other analyses the high expression of TLR2 in
monocytes in high thrombocytosis which appears to be a
selective biomarker to high death risk. The network shows
TLR2 and TLR4 from neutrophils and monocytes making
connections among them and with CD4+CD69+ T-cells.
The circulating cell-free DNA in SCA patients even at
steady state can be recognized by TLR9 [61, 62]. Perhaps in
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our SCA patients at steady state, the hemolysis process and
the release of heme are contained, not releasing sufficiently
high concentrations to induce upregulation of TLRs 2 and
4, however sufficient to induce TLR9 expression. Besides that,
we could observe by analyzing the biomarker network that
TLR9 in neutrophils and monocyte makes a positive connec-
tion with B-cells both in high reticulocytosis and high death
risk. This correlation can indicate that TLR9 stimulation
induces maturation of antigen-presenting cells favoring a
Th1 immune response and stimulates antigen-independent
B-cell proliferation [63, 64].
We are the first to show the profile of classical or myeloid
and plasmacytoid DC subsets in SCA patients at steady state.
In both subsets, the frequency was low in the SCA patients
compared to HD. Urban et al. [65] evaluated cDC and pDC
frequencies in children with α-thalassemia and the sickle cell
trait. They showed a significant reduction of mDC frequency
in children homozygous for α-thalassemia whether or not
they were also carriers for HbS (AA -α/-α and AS -α/αα,
AS -α/-α) compared to normal healthy children (AA αα/αα)
[65]. They suggest that the most likely possibilities are
reduced mDC production in the bone marrow or chronic
activation and enhanced retention of mDCs in the spleen.
Sickle cell disease (SCD) is associated with alterations in
immune phenotypes [66], and we decided to evaluate NK
and NKT frequencies on SCA patients at steady state.
Recently, ischemia-reperfusion injury (IRI) with resultant
white cell activation has been implicated as an additional
contributor to the pathophysiology of SCD [67]. Our results
showed low frequencies of NK and NKT cells in SCA patients
at steady state. In ElAlfy et al.’s [66] study, they showed that
NK cell frequency was higher in all patients with SDC com-
pared with controls, but the difference was not significant.
Furthermore, they showed elevated counts of NK cells with
higher levels of IFN-γ, so these cells were activated in SCA
patients. They suppose that the increased number of NK cells
among their patients was associated with a history of fre-
quent vasoocclusive crisis, but they could not compare
patients with vasoocclusive crisis and those with stable
SCD. Kaplan et al. [68] showed lower NK activity in SCA
patients who received repeated blood transfusion compared
to normal controls.
The activation of RBCs, leucocytes, platelets, and endo-
thelial cells leads to the increased production of proinflam-
matory and anti-inflammatory cytokines, which gives SCA
characteristics of a chronic inflammatory disease [69]. Our
results showed increased levels of Th1 and Th17 cytokine
profiles (IFN-γ, IL-12, and IL-17) and an inflammatory and
regulatory cytokine pattern (IL-1β, IL-6, IL-4, and IL-10) in
SCA patients at steady state. The chemokines IL-8, IP-10,
MIP-1α, MIP-1β, and RANTES and the growth factors
VEGF, FGF-basic, and GM-CSF were higher in SCA patients.
There are a few reports in the literature pertaining to the
role of IL-12 and IL-17 in SCA [10, 69]. Unlike our results,
Taylor et al. [70] did not observe detectable levels of IL-12
in SCA patients at steady state compared to healthy control
subjects; however, as in our study, they observed high levels
of IFN-γ. In SCA patients from Oman City, the mean serum
level of IFN-γ was higher in both steady state (95.71 pg/mL)
and crisis patients (90.13 pg/mL) compared to control sub-
jects (74.42 pg/mL) [71]. Thus, IL-12 can also negatively
affect the development, homeostasis, and function of nTreg
cells by limiting IL-2 expression [71]. The immunoregulatory
functions of IFN-γ are diverse and include the activation of
mononuclear phagocytes and neutrophils and the upregula-
tion of class I molecules of the major histocompatibility com-
plex (MHC-1). IL-2 signaling promotes the development of
both Th1 and Th2 cell types by inducing the expression of
IL-12Rβ2 and IL-4Rα, respectively [72], and has been
reported the suppress Th17 development inhibiting IL-17
production [72].
The role of IL-17 in SCA are not well understood [69].
Corroborating with our results, Vilas-Boas et al. [10] and
Pitanga et al. [69] observed higher levels of IL-17 in SCA
patients at steady state than in healthy donors. Vilas-Boas
et al. still found a positive association between homocysteine
and IL-17 and suggest a possible role of homocysteine in the
induction of IL-17. We also observed high levels of IL-17 in
high thrombocytosis. Bouchnita et al. [73] demonstrated that
IL-17 enhanced the level of platelet aggregation from 20% to
45-50% and led to thrombosis and vessel occlusion.
Increased levels of IL-1β, IL-6, and TNF-α have been
reported in serum from patients with SCD [69, 71, 74–77].
Selvaraj et al. [76] showed that monocytes isolated from
SCD patients are in a highly activated state as demonstrated
by increased gene expression of IL-1β as well as TNF-α com-
pared with monocytes from healthy individuals. Our results
showed detectable levels of TNF-α in SCA patients at steady
state, but no significant differences. Pathare et al. [71] showed
very similar levels of TNF-α between SCA patients at steady-
state and the control group, but in patients in crisis, the level
was higher compared to the control group, despite the non-
significant difference.
Chemokines contribute to SDC pathogenesis by acting
on leucocytes [77]. The IL-8 is involved in both endothelial
cell proliferation and angiogenesis produced by several types
of cells such neutrophils, macrophages, endothelial cells and
induces leucocyte chemotaxis and neutrophil degranulation
[69, 77]. Elevated levels of IL-8 are observed in SDC patients
during crises and have been proposed to be a vasoocclusion
crises predictor [78]. Pathare et al. [71] observed, like our
results, significantly high levels of IL-8 in SCA patients at
steady state compared to healthy donors, and despite having
observed a higher level in patients in crisis, there was no sig-
nificant difference between steady state and crises. Hazin-
Costa et al. [79] also observed high levels of IL-8 in SDC
patients at steady state compared to healthy donors.
MIP-1α and MIP-1β are chemokines with inflammatory
properties that are highly related and share 68% identical
amino acids [80]. Selvaraj et al. [76] showed a high expres-
sion of MIP-1β in monocytes activated from SDC patients
compared to monocytes from healthy individuals. Wu et al.
[81] demonstrated in autoimmune hemolytic anemia that
an elevated circulating level of MIP-1β indicates a boost in
erythroid proliferation and reticulocytosis. It is possible that
in SCA, this chemokine can be acting that way. Preclinical
studies have further demonstrated that MIP-1α is released
upon the induction of Th1 responses and by neutrophils
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and monocytes during monocyte-endothelial cell interac-
tions that serves as an important mechanism in sustaining
the recruitment of cells during inflammatory responses
[80]. In SCA, MIP-1α is possibly also mediating this mecha-
nism. Also, we observed a high level of MIP-1α in high
thrombocytosis. Klinger et al. [82] showed that MIP-1α is
present within the α-granules of human platelets.
An enhanced expression of MCP-1 was demonstrated in
a variety of pathologic conditions associated with inflamma-
tion and mononuclear cell infiltration [83]. A higher level of
MCP-1 is also associated with the development of polarized
Th2 responses [84]. However, our results as well as those of
Hazin-Costa et al. [79] did not show a statistical difference
in the MCP-1 level between SCA patients at steady state
and healthy donors. Although SCA is a chronic inflamma-
tory disease, MCP-1 may be inhibited by the presence of
the heme oxygenase 1 (HO-1) enzyme, which is increased
in SCA patients [85, 86]. Sickle erythrocytes release large
amounts of hemoglobin after hemolysis, and endothelial
HO-1 induction may serve to control excessive heme over-
load [86].
Unlike our results, significant levels of RANTES and IP-
10 between SCA patients at steady state and healthy donors
was not shown by Hazin-Costa et al.’s results [79]. However,
Driss et al. [87] showed elevated serum levels of IP-10 in
patients with homozygous sickle cell disease. In the SCA
pathophysiology, RANTES still induces the activation of the
Gardos channel (Ca-dependent K+ channel) in sickle eryth-
rocytes by an increased affinity constant for intracellular
Ca+ resulting in intracellular depletion of K+ and dehydra-
tion of sickle red blood cells [88]. Apparently, in SCA,
RANTES can be important for the perivascular recruitment
of IFN-γ-producing T-cells which may affect vascular dys-
function [89].
There are conflicting reports on the role of IL-4 and IL-10
anti-inflammatory cytokines in SCA patients [69]. Pathare
et al. [71] and Raghupathy et al. [90] demonstrated signifi-
cantly higher levels of IL-4 in SCA patients at steady state like
our results. Taylor et al. [91] also demonstrated higher levels
of IL-4 and IL-10 in SCA patients at steady state, even though
Cavalcante et al. [92] did not show significantly different
serum levels of IL-10 between steady state SCA patients
and control subjects. Musa et al. [14] demonstrated higher
levels of IL-4 in SCA patients in vasoocclusive crises than in
steady state and control subjects; however, their levels of
IL-10 were higher in SCA patients at steady state than in cri-
ses and control individuals corroborating our results. The
exacerbated inflammatory process within the vascular envi-
ronment of the SCA patients could be responsible for trigger-
ing the compensatory Th2 responses emphasizing the role of
an injured endothelium and activated monocytes [93]. The
other Th2 cytokines, IL-5 and IL-13, were not elevated in
SCA patients at steady state compared to healthy donors
unlike what has been demonstrated by Veiga et al. [93]. Pos-
sibly, in our SCA patients, the high levels of IL-17 can be
affecting IL-5 and IL-13 production.
T-cell homeostasis requires a balance in programs
underlying activation and apoptosis with those controlling
quiescence and survival. In healthy, T-cell-replete animals,
naive CD4 T-cells are sustained by self-peptide and IL-7 sig-
nals [94]. We did not demonstrate a significant difference in
IL-7 levels between SCA patients and healthy donors. How-
ever, in SCA, due to the high levels of activated TCD4+ and
TCD8+ lymphocytes, the IL-7 level maybe be controlled by
negative feedback.
Angiogenesis is a highly regulated process and requires
coordinated signaling events among a variety of angiogenic
factors [95]. Gürkan et al. [96], Solovey et al. [97], and Cao
et al. [98] demonstrated higher levels of VEGF and FGF-
basic in HbSS patients at steady state corroborating our
results and even higher levels in SCA patients with painful
vasoocclusive crises. Nevertheless, even platelet activation
has also been proposed as a significant contributing factor
to the pathogenesis of and outcome of SCD patients [99].
However, they showed that SCA patients during vasoocclu-
sive crises had higher levels of PDGF compared to healthy
controls and steady state.
Regarding the colony-stimulating factor, only GM-CSF
was higher in SCA patients at steady state compared to
healthy donors, while G-CSF was not significantly different.
Conran et al. [100] demonstrated that circulating levels of
GM-CSF in steady-state patients with SCD were significantly
higher than in healthy controls, and G-CSF levels were signif-
icantly lower. Besides that, they demonstrated that GM-CSF
levels correlated significantly with the numbers of total leu-
kocytes in SCA patients, but G-CSF had a significantly nega-
tive correlation. GM-CSF can be responsible, at least in part,
for the leukocytosis observed with SCD, and proinflamma-
tory cytokines like IL-1β, which are increased in SCD, can
be associated with elevated levels of GM-CSF [100].
As discussed above and by the signature and biomarker
network analyses, SCA pathophysiology at steady state
appears to be controlled by Th1 and Th17 cytokines (IL-12,
IFN-γ, IL-1β, and IL-17), with IL-8, IL-10, and IP-10 as gen-
eral biomarkers and MIP-1β and RANTES making a differ-
ence in SCA patients with high death risk. Besides, due to
its antiangiogenic activity [101], IL-12 appears to control
VEGF regardless of any laboratory and clinical condition,
IL-10 appears to control endothelial adhesion by IP-10 corre-
lation, and MIP-1β appears to stimulate Th17 response by
IL-17 correlation. In high reticulocytosis and death risk, there
appears to be a competition of the Th1 and Th17 inflamma-
tory responses with Th2 due to the correlations of TNF-α/IL-
1β/MIP-1α, IFN-γ/IL-13, IL-17/IL-4, and IL-4/IL-2. In high
thrombocytosis, we observed VEGF making several connec-
tions with chemokines and cytokines.
In conclusion, our results demonstrated that in SCA
pathophysiology at steady state, there is a broad immunolog-
ical biomarker crosstalk highlighted by TCD4+ lymphocytes;
TLR2 in monocytes; VLA-4 in TCD8+ lymphocytes; Th1,
Th17 inflammatory, and IL-10 regulatory cytokines; MIP-
1α, MIP-1β, and IP-10 chemokines; and growth factor
VEGF. High levels of MIP-1β and RANTES appear to be rel-
evant in a high death risk condition. High reticulocytosis and
high death risk conditions present common correlations;
there seems to be a balance by Th2 profile. Nevertheless,
more studies approaching the same biomarkers in the same
patients in crisis or other biomarkers, intracellular signaling
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pathways, and analysis of gene expression of molecules
involved in innate and adaptive immune responses are
needed to better understand this complex pathophysiological
mechanism of SCA.
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